{{medical}}
{{unreferenced|time=2012-04-24T18:26:52+00:00}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459981210
| IUPAC_name = (''RS'')-1-(''tert''-butylamino)-3-[(2-methyl-1''H''-indol-4-yl)oxy]propan-2-yl benzoate
| image = Bopindolol.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|bopindolol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 62658-63-3
| ATC_prefix = C07
| ATC_suffix = AA17
| ATC_supplemental =  
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 357995
| PubChem = 44112
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08807
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 40146
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KT304VZO57
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D07537

<!--Chemical data-->
| chemical_formula =  
| C=23 | H=28 | N=2 | O=3 
| molecular_weight = 380.48 g/mol
| smiles = CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UUOJIACWOAYWEZ-UHFFFAOYSA-N
}}

'''波吲洛尔'''（Bopindolol）别名吲苯脂心安，β受体阻滞剂。药理作用对β1、β2受体阻断无选择性，具有一定的同在拟交感活性。作用类似[[吲哚洛尔|吲哚洛尔]]，但强10倍，也具有降低血浆肾素活性的作用。

{{Template:Β受体阻滞剂}}


[[Category:Β阻滞药|Category:Β阻滞药]]